Mandate

Vinge has advised Vicore Pharma Holding AB (publ) in connection with directed share issuances

Vinge has advised Vicore Pharma Holding AB (publ) in connection with directed share issuances, whereby Vicore Pharma receives gross proceeds of SEK 500 million.

The share issuances were directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. One of the issuances is conditional upon approval by an extraordinary general meeting and that a prospectus is published. Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).

Vinge’s team has consisted of Rikard Lindahl, Joel Magnusson and Annie Fällström.

Related

Vinge has advised Alder on the establishment of Alder III

Vinge has advised Alder on the establishment of Alder's third and largest fund to date, Alder III.
May 27, 2024

Vinge has advised Triton in connection with sale of shares in Ambea AB (publ)

In total, 7.6 million shares were placed at a price of SEK 64 per share, corresponding to a total value of approximately SEK 489 million.
May 27, 2024